M&M Financial Services gets nod to raise Rs10,000 crore
M&M Financial will issue ‘secured redeemable non-convertible debentures and/or unsecured subordinated redeemable NCDs of face value of Rs1,000 each for an amount up to rupees 10 thousand crores
New Delhi: Mahindra & Mahindra Financial Services on Friday said that it has received approval from Registrar of Companies to raise up to Rs10,000 crore through non-convertible debentures.
The company informed stock exchanges that it will issue “secured redeemable non-convertible debentures and/or unsecured subordinated redeemable non-convertible debentures of face value of Rs1,000 each for an amount up to Rupees 10 thousand crores”.
The NCDs will be issued in one or more tranches up to the shelf limit of Rs10,000 crore, it added.
Tranche 1 of the “issue consists of secured redeemable non-convertible debentures of face value of Rs1,000 each and/ or Unsecured, subordinated, redeemable non-convertible debentures of face value of Rs1,000 each (unsecured NCDs) for an amount aggregating up to Rs500 crore (”base issue size”) with an option to retain oversubscription up to Rs3,000 crore aggregating up to Rs3,500 crore”.
The secured NCDs will be allotted for a value of up to Rs2,500 crore and the unsecured NCDs will be allotted for a value of up to Rs1,000 crore within the overall limit of Rs3,500 crore, the company said.
“The unsecured NCDs will be eligible for Tier II Capital,” it added.
Editor's Picks »
- Opinion | The ‘stuck’ Naga peace talks need a reimagining
- #10YearChallenge: The meme game that’s taking the Internet by storm
- Theresa May government faces no-confidence vote after Brexit defeat
- US retailer Sears saved from the brink for time being: reports
- Sabarimala row: After the Left’s lakhs-strong ‘Women’s Wall’, the Right’s to rally lakhs of pro-ban supporters in Kerala
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers